
Mitochondrial Open Reading Frame of the 12S rRNA-c
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene — a signaling molecule bridging mitochondrial function with immune regulation, metabolic flexibility, and cellular stress response. Often called a "mitochondrial hormone," MOTS-c represents a frontier of longevity and immune science.
Physician review required · Ships in 48h after approval · All 50 states
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded not by the nuclear genome, but by the mitochondrial genome — the DNA inside your cells' energy-producing organelles. This makes it biologically distinct from every other peptide in the BRAVO1 catalog. Rather than being produced in the nucleus, MOTS-c is synthesized inside the mitochondria themselves and released as a signaling molecule that communicates the health status of your mitochondria to the rest of the body.
Think of MOTS-c as a messenger from your mitochondria. When mitochondria are under stress — from aging, oxidative damage, or metabolic dysfunction — MOTS-c levels decline. Supplementing MOTS-c restores this signaling, promoting immune regulation, metabolic resilience, and cellular stress response. Research has shown it can translocate to the cell nucleus during stress and regulate gene expression directly, blurring the line between peptide and hormone.
MOTS-c is increasingly recognized as a key longevity factor: its levels naturally decline with age, it is elevated in centenarians, and it has been called an "exercise mimetic" for its ability to activate AMPK — the same cellular energy sensor triggered by physical activity — even without exercise.
MOTS-c plays a direct role in immune homeostasis by modulating the inflammatory response through its effects on mitochondrial function. Mitochondria are central regulators of immune cell activation — they generate the metabolic fuel that powers immune responses and control the release of reactive oxygen species (ROS) that drive inflammation. MOTS-c helps prevent excessive immune activation, promoting balanced immune responses rather than chronic inflammatory states. Research has shown MOTS-c reduces pro-inflammatory cytokines including TNF-α and IL-6 while supporting regulatory immune pathways.
MOTS-c activates AMPK (AMP-activated protein kinase) — the body's cellular energy sensor, which is normally triggered by exercise, fasting, or caloric restriction. AMPK activation drives glucose uptake, fat oxidation, mitochondrial biogenesis, and cellular cleanup (autophagy). By activating AMPK, MOTS-c produces metabolic and cellular benefits similar to exercise — including improved insulin sensitivity, reduced fat accumulation, and enhanced cellular resilience — without requiring physical exertion. This is particularly significant for those whose metabolic function is compromised by aging, illness, or inactivity.
Research has shown that MOTS-c improves insulin sensitivity and glucose metabolism through AMPK-dependent and independent pathways. In animal models, MOTS-c administration prevented diet-induced obesity and reversed insulin resistance. It promotes the body's ability to switch between fuel sources — a hallmark of metabolic health — and has been studied for its potential role in type 2 diabetes and metabolic syndrome.
One of MOTS-c's most remarkable properties is its ability to translocate from the cytoplasm to the cell nucleus in response to cellular stress. Once in the nucleus, it acts as a transcription co-activator — directly influencing gene expression related to stress response, antioxidant defense, and metabolic adaptation. This nuclear signaling role makes MOTS-c a true mitochondrial-nuclear communication molecule, not simply a receptor-binding peptide.
MOTS-c levels decline with age and are elevated in exceptionally long-lived individuals (centenarians) compared to age-matched controls. It has been shown to extend lifespan in animal models and to reverse age-related metabolic decline. Its effects on mitochondrial function, cellular stress response, AMPK activation, and immune regulation position it as one of the most mechanistically grounded longevity peptides currently under research.
MOTS-c is administered via subcutaneous injection. Dosage, frequency, and protocol duration are determined through the BRAVO1 physician review process based on your individual health profile, immune status, and goals. Do not self-administer any peptide protocol without physician oversight.
View certificate of analysis and batch testing for MOTS-c.
Start the physician review process for MOTS-c. Ships within 48 hours of approval to all 50 states.
Start Physician Review →This website is intended for educational and informational purposes only. Products and services are subject to physician review and approval. Information provided is not medical advice. These statements have not been evaluated by the FDA.